A carregar...
Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies
IMPORTANCE: Many large adjuvant clinical trials end up underpowered because of fewer than expected events in the control arm. Ensuring a minimum number of events would result in more informative trials. OBJECTIVE: To calculate individualized residual risk estimates using residual risk prediction sof...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885272/ https://ncbi.nlm.nih.gov/pubmed/29372234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5092 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|